Navicare Biotech Co., Ltd.(TW:8472)
NT$52.90+4.75 (+9.87%)
TW:8472
Navicare Biotech Co., Ltd. financials statements
NT$52.90
At close:+4.75 (+9.87%)
Navicare Biotech Co., Ltd. (8472) Ratios
Navicare Biotech Co., Ltd. Ratios
TW:8472's free cash flow for Q2 2026 was NT$-28.96M. For the 2026 fiscal year, TW:8472's free cash flow was increased by NT$0.00 and operating cash flow was NT$-28.96M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Mar 23 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.68 | 0.42 | 0.59 | 0.72 | 1.59 |
| Quick Ratio | 0.61 | 0.33 | 0.55 | 0.69 | 1.59 |
| Cash Ratio | 0.29 | 0.14 | 0.13 | 0.19 | 0.27 |
| Solvency Ratio | -0.01 | -0.08 | -0.04 | -0.09 | 0.04 |
| Operating Cash Flow Ratio | -0.01 | -0.11 | -0.17 | -0.11 | -0.14 |
| Short-Term Operating Cash Flow Coverage | -0.03 | -0.57 | -1.25 | -1.07 | 0.49 |
| Net Current Asset Value | NT$ -408.77M | NT$ -481.46M | NT$ -437.07M | NT$ -351.72M | NT$ 279.33M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.31 | 0.26 | 0.21 | 0.19 | 0.01 |
| Debt-to-Equity Ratio | 1.21 | 0.92 | 0.68 | 0.56 | 0.03 |
| Debt-to-Capital Ratio | 0.55 | 0.48 | 0.41 | 0.36 | 0.02 |
| Long-Term Debt-to-Capital Ratio | 0.45 | 0.33 | 0.29 | 0.28 | 0.00 |
| Financial Leverage Ratio | 3.88 | 3.51 | 3.25 | 2.92 | 1.99 |
| Debt Service Coverage Ratio | -0.16 | -0.47 | -0.33 | -1.09 | -0.13 |
| Interest Coverage Ratio | -4.20 | -13.72 | -18.08 | -31.68 | 40.39 |
| Debt to Market Cap | 0.26 | 0.55 | 0.36 | 0.30 | -0.16 |
| Interest Debt Per Share | 18.86 | 15.03 | 14.31 | 13.19 | 0.76 |
| Net Debt to EBITDA | -11.15 | -3.37 | -3.48 | -1.43 | -5.48 |
| Profitability Margins | |||||
| Gross Profit Margin | 36.01% | 62.86% | 72.54% | 84.48% | 93.00% |
| EBIT Margin | -6.66% | -21.58% | -16.33% | -28.44% | 5.04% |
| EBITDA Margin | -3.16% | -16.04% | -12.03% | -24.72% | 7.36% |
| Operating Profit Margin | -6.66% | -22.78% | -23.21% | -16.12% | 3.97% |
| Pretax Profit Margin | -4.34% | -23.24% | -17.62% | -28.95% | 4.95% |
| Net Profit Margin | -4.87% | -23.28% | -13.34% | -24.94% | 3.53% |
| Continuous Operations Profit Margin | -4.87% | -23.28% | -13.34% | -25.73% | 3.48% |
| Net Income Per EBT | 112.06% | 100.18% | 75.73% | 86.14% | 71.35% |
| EBT Per EBIT | 65.26% | 102.00% | 75.91% | 179.57% | 124.60% |
| Return on Assets (ROA) | -2.22% | -7.85% | -4.38% | -6.82% | 1.03% |
| Return on Equity (ROE) | -8.60% | -27.52% | -14.26% | -19.91% | 2.04% |
| Return on Capital Employed (ROCE) | -6.31% | -17.37% | -16.91% | -9.05% | 2.22% |
| Return on Invested Capital (ROIC) | -5.24% | -13.76% | -10.89% | -7.18% | 2.06% |
| Return on Tangible Assets | -2.23% | -7.89% | -4.41% | -6.86% | 1.03% |
| Earnings Yield | -1.84% | -17.01% | -7.90% | -11.10% | 1.20% |
| Efficiency Ratios | |||||
| Receivables Turnover | 6.29 | 10.85 | 3.55 | 8.39 | 9.25 |
| Payables Turnover | 1.23 | 0.53 | 0.34 | 0.17 | 0.09 |
| Inventory Turnover | 8.37 | 2.48 | 4.08 | 2.82 | 1068.30 |
| Fixed Asset Turnover | 1.70 | 1.14 | 1.42 | 1.36 | 17.99 |
| Asset Turnover | 0.46 | 0.34 | 0.33 | 0.27 | 0.29 |
| Working Capital Turnover Ratio | -1.91 | -1.14 | -1.75 | 5.44 | 1.03 |
| Cash Conversion Cycle | -194.03 | -506.74 | -872.74 | -1927.85 | -3934.15 |
| Days of Sales Outstanding | 58.04 | 33.63 | 102.83 | 43.52 | 39.46 |
| Days of Inventory Outstanding | 43.61 | 147.09 | 89.37 | 129.66 | 0.34 |
| Days of Payables Outstanding | 295.68 | 687.47 | 1064.94 | 2101.03 | 3973.95 |
| Operating Cycle | 101.65 | 180.72 | 192.20 | 173.18 | 39.80 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.18 | -3.58 | -6.10 | -3.86 | -3.87 |
| Free Cash Flow Per Share | -0.23 | -4.07 | -8.20 | -26.76 | -4.20 |
| Dividend Paid and CapEx Coverage Ratio | -3.30 | -7.27 | -2.91 | -0.16 | -1.37 |
| Capital Expenditure Coverage Ratio | -3.30 | -7.27 | -2.91 | -0.17 | -11.91 |
| Operating Cash Flow Coverage Ratio | -0.01 | -0.24 | -0.43 | -0.29 | -5.18 |
| Operating Cash Flow to Sales Ratio | -0.01 | -0.19 | -0.28 | -0.21 | -0.23 |
| Free Cash Flow Yield | -0.33% | -15.66% | -22.15% | -63.71% | -8.31% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -54.43 | -5.90 | -12.67 | -9.01 | 82.79 |
| Price-to-Sales (P/S) Ratio | 2.65 | 1.37 | 1.69 | 2.25 | 2.93 |
| Price-to-Book (P/B) Ratio | 4.68 | 1.62 | 1.81 | 1.79 | 1.70 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -307.21 | -6.38 | -4.51 | -1.57 | -12.03 |
| Price-to-Operating Cash Flow Ratio | -400.20 | -7.26 | -6.07 | -10.89 | -13.04 |
| Price-to-Earnings Growth (PEG) Ratio | 0.77 | -0.12 | 0.34 | 0.01 | -1.08 |
| Enterprise Value Multiple | -95.10 | -11.90 | -17.51 | -10.51 | 34.39 |
| Enterprise Value | 1.43B | 643.12M | 818.76M | 861.72M | 772.61M |
| EV to EBITDA | -95.10 | -11.90 | -17.51 | -10.51 | 34.39 |
| EV to Sales | 3.00 | 1.91 | 2.11 | 2.60 | 2.53 |
| EV to Free Cash Flow | -348.03 | -8.90 | -5.63 | -1.82 | -10.38 |
| EV to Operating Cash Flow | -453.37 | -10.13 | -7.57 | -12.60 | -11.25 |
| Tangible Book Value Per Share | 14.95 | 15.78 | 20.16 | 23.08 | 29.42 |
| Shareholders’ Equity Per Share | 15.23 | 16.07 | 20.50 | 23.42 | 29.73 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.12 | -0.00 | 0.24 | 0.11 | 0.30 |
| Revenue Per Share | 26.91 | 19.00 | 21.90 | 18.69 | 17.21 |
| Net Income Per Share | -1.31 | -4.42 | -2.92 | -4.66 | 0.61 |
| Tax Burden | 1.12 | 1.00 | 0.76 | 0.86 | 0.71 |
| Interest Burden | 0.65 | 1.08 | 1.08 | 1.02 | 0.98 |
| Research & Development to Revenue | 0.03 | 0.05 | 0.07 | 0.09 | 0.10 |
| SG&A to Revenue | 0.43 | 0.80 | 0.89 | 0.95 | 0.88 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.15 | 0.81 | 1.58 | 0.71 | -4.55 |
Currency in TWD
